First-to-Market Edge for Apellis's Syfovre in Geographic
Prospects for Syfovre uptake and trust in Apellis take a plunge following reports of intraocular inflammation, according to Spherix Global Insights...
Source: globenewswire.com
Page 2 - Time Dynamix News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Time Dynamix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Time Dynamix Today - Breaking & Trending Today
At Eighteen Months Post-Launch, Impel's Trudhesa Has Struggled to Keep Up with Pfizer's Nurtec ODT and AbbVie's Ubrelvy, According to Spherix Global Insights
/PRNewswire/ -- Spherix Global Insights recently released data from their Launch Dynamix™: Trudhesa in Acute Treatment of Migraine (US) deep dive study...
Source: prnewswire.com
Genentech's Vabysmo Well-Received Amongst Ophthalmologists, but Use Continues to Lag the Competition, According to Spherix Global Insights
/PRNewswire/ -- According to Spherix Global Insights' Launch Dynamix™: Vabysmo service, to no surprise, Regeneron's Eylea continues to lead the charge in both...
Source: prnewswire.com
Familiarity with GSK's Jesduvroq® (daprodustat) Likely to Be Strong Driver of Adoption in Dialysis, According to Spherix Global Insights
/PRNewswire/ -- In the 32nd wave of ongoing tracking of the U.S. Renal Anemia market, Spherix surveyed 207 US nephrologists about overall patient management...
Source: prnewswire.com
US Neurologists Cautiously Optimistic About Potential Approval of Pfizer's Zavegepant for the Acute Treatment of Migraine, According to Spherix Global Insights
/PRNewswire/ -- On February 16, The Lancet Neurology published the Phase 3 results of Pfizer's zavegepant for the acute treatment of migraine. The CGRP...
Source: prnewswire.com